A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs GX I7 (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections; Leucopenia; Solid tumours
- Focus Adverse reactions
- Sponsors Genexine
- 13 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2018.
- 13 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
- 25 Aug 2016 New trial record